Galena Biopharma (GALE) Reports Q4 Loss Per Share of 6c, Reiterates FY15 Rev. Guidance

Galena Biopharma (NASDAQ: GALE) reported Q4 EPS of ($0.06), may not compare to the analyst estimate of ($0.11). Revenue for the quarter came in at $3.2 million versus the consensus estimate of $2.58 million.

Galena reiterated 2015 net revenue guidance between $15-$18 million for the combined commercial programs.

For earnings history and earnings-related data on Galena Biopharma (GALE) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• DA Davidson Reiterates Buy Rating on Walmart (WMT) Ahead of Earnings
• DA Davidson Reiterates Buy Rating on Boost Run (BRUN)